Adagio Halts Trials Assessing Its COVID-19 Antibody

Adagio Therapeutics is stopping two phase 2/3 studies of its experimental COVID-19 monoclonal antibody, ADG20, after the treatment was shown to be less effective against the Omicron variant.

But the Waltham, Mass., company is not giving up on the drug candidate. It is now in discussions with the FDA over its dosing strategy and could possibly add a higher dosing arm in the two trials after pausing enrollment of new patients in the 300-mg dose cohorts.

Although the antibody shows reduced potency against Omicron, it is “among the few to demonstrate neutralizing activity against the Omicron variant and warrants its continued development,” said Laura Walker, Adagio’s co-founder and chief scientific officer.